Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics

Go back to Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
(NASDAQ: GMAB) Delayed: 32.84 +0.90 (2.82%)
Previous Close $31.94    52 Week High
Open $32.31    52 Week Low
Day High $32.94    P/E N/A 
Day Low $32.28    EPS
Volume 3,432,021